| Applications: |
Immunodepletion/Immunocompetition |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
PTP alpha Blocking Peptide is synthetically produced from the 650-700 sequence and is suitable for use in western blot applications. |
| Formulation: |
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Gene Symbol: |
PTPRA |
| Gene ID: |
5786 |
| Uniprot ID: |
PTPRA_HUMAN |
| Immunogen Region: |
650-700 |
| Immunogen: |
Synthetic peptide taken within amino acid region 650-700 on human Receptor-type tyrosine-protein phosphatase Alpha protein. |
| Post Translational Modifications | Integrin binding to extracellular matrix induces phosphorylation at Tyr-798 which induces PTPRA localization and recruitment of BCAR3, BCAR1 and CRK to focal adhesions. |
| Function | Tyrosine protein phosphatase which is involved in integrin-mediated focal adhesion formation. Following integrin engagement, specifically recruits BCAR3, BCAR1 and CRK to focal adhesions thereby promoting SRC-mediated phosphorylation of BRAC1 and the subsequent activation of PAK and small GTPase RAC1 and CDC42. |
| Peptide Name | Receptor-Type Tyrosine-Protein Phosphatase AlphaProtein-Tyrosine Phosphatase AlphaR-Ptp-Alpha |
| Database Links | Reactome: R-HSA-375165Reactome: R-HSA-5673001 |
| Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane ProteinCell JunctionFocal AdhesionLocalizes To Focal Adhesion Sites Following Integrin Engagement |
| Alternative Peptide Names | Receptor-Type Tyrosine-Protein Phosphatase Alpha proteinProtein-Tyrosine Phosphatase Alpha proteinR-Ptp-Alpha proteinPTPRA proteinPTPA proteinPTPRL2 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
